Literature DB >> 35146565

Typical linear radial periventricular enhancement in a patient with glial fibrillary acidic protein (GFAP) astrocytopathy.

Jingfang Lin1, Lu Lu1, Jinmei Li2.   

Abstract

OBJECTIVE: We describe an unusual case of corticosteroid-responsive autoimmune meningoencephalomyelitis with linear perivascular gadolinium enhancement but in the absence of anti- glial fibrillary acidic protein (GFAP) antibodies (ABs) in the cerebral spinal fluid (CSF).
METHODS: The patient's clinical symptoms, brain magnetic resonance imaging (MRI) features, serum and CSF analysis and treatment were reviewed.
RESULTS: A 47-year-old female experienced a subacute course with bilateral lower limbs weakness, unsteady walking, and dysuria. Brain MRI revealed typical radial perivascular gadolinium enhancement extending from the lateral ventricles to the white matter; MRI spine revealed lesions distributed in the entire spinal cord. Immunohistochemical staining of a brain biopsy revealed CD3+ T cells and CD20+ B cells cuffing around brain vessels, accompanied by CD68+ macrophages. CSF was negative for anti-GFAP ABs while serum was positive for anti-GFAP ABs (1:100). The patient responded well to corticosteroid.
CONCLUSIONS: There are no uniform diagnostic criteria for autoimmune GFAP astrocytopathy. Our case suggested the importance of typical MRI findings in the diagnosis of this rare disease. Early treatments are very important to alleviate symptoms.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Antibody and brain immunohistopathology; Glial fibrillary acidic protein; Linear radial periventricular enhancement

Mesh:

Substances:

Year:  2022        PMID: 35146565     DOI: 10.1007/s10072-022-05937-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  1 in total

1.  GFAP antibody-negative myelitis with high similarity to autoimmune GFAP astrocytopathy: a case report.

Authors:  Yi-Ming Zhang; Shen Liu; Ting-Ting Liu; Hong-Dong Zhao; Jian-Quan Shi
Journal:  Neurol Sci       Date:  2022-05-18       Impact factor: 3.830

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.